Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
NYSE:SNY's Cash to Debt is ranked higher than
84% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.45 vs. NYSE:SNY: N/A )
Ranked among companies with meaningful Cash to Debt only.
NYSE:SNY' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.56 Max: 10.62
Current: N/A
0.14
10.62
Equity to Asset 0.57
NYSE:SNY's Equity to Asset is ranked lower than
60% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:SNY: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:SNY' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.57
0.48
0.65
Interest Coverage 9.76
NYSE:SNY's Interest Coverage is ranked lower than
66% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.06 vs. NYSE:SNY: 9.76 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:SNY' s Interest Coverage Range Over the Past 10 Years
Min: 8.34  Med: 12.02 Max: 19.65
Current: 9.76
8.34
19.65
F-Score: 5
Z-Score: 1.94
M-Score: -2.34
WACC vs ROIC
8.56%
12.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.86
NYSE:SNY's Operating margin (%) is ranked higher than
73% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. NYSE:SNY: 15.86 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:SNY' s Operating margin (%) Range Over the Past 10 Years
Min: 15.25  Med: 17.82 Max: 20.7
Current: 15.86
15.25
20.7
Net-margin (%) 12.84
NYSE:SNY's Net-margin (%) is ranked higher than
73% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. NYSE:SNY: 12.84 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:SNY' s Net-margin (%) Range Over the Past 10 Years
Min: 11.16  Med: 14.35 Max: 18.02
Current: 12.84
11.16
18.02
ROE (%) 12.74
NYSE:SNY's ROE (%) is ranked higher than
68% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. NYSE:SNY: 12.74 )
Ranked among companies with meaningful ROE (%) only.
NYSE:SNY' s ROE (%) Range Over the Past 10 Years
Min: 6.51  Med: 8.75 Max: 11.7
Current: 12.74
6.51
11.7
ROA (%) 7.31
NYSE:SNY's ROA (%) is ranked higher than
68% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. NYSE:SNY: 7.31 )
Ranked among companies with meaningful ROA (%) only.
NYSE:SNY' s ROA (%) Range Over the Past 10 Years
Min: 3.78  Med: 5.46 Max: 7.04
Current: 7.31
3.78
7.04
ROC (Joel Greenblatt) (%) 58.74
NYSE:SNY's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. NYSE:SNY: 58.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:SNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.74  Med: 43.07 Max: 63.92
Current: 58.74
31.74
63.92
Revenue Growth (3Y)(%) -0.80
NYSE:SNY's Revenue Growth (3Y)(%) is ranked lower than
69% of the 602 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NYSE:SNY: -0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:SNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1  Med: 5.55 Max: 27.3
Current: -0.8
-1
27.3
EBITDA Growth (3Y)(%) -3.60
NYSE:SNY's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NYSE:SNY: -3.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:SNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10  Med: 2.45 Max: 49.3
Current: -3.6
-10
49.3
EPS Growth (3Y)(%) -3.70
NYSE:SNY's EPS Growth (3Y)(%) is ranked lower than
65% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:SNY: -3.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:SNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.5  Med: -0.05 Max: 41.7
Current: -3.7
-11.5
41.7
» NYSE:SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SNY Guru Trades in Q2 2015

Lee Ainslie 101,650 sh (New)
John Buckingham 132,190 sh (+437.18%)
Dodge & Cox 49,765,693 sh (+15.64%)
Manning & Napier Advisors, Inc 2,879,307 sh (+15.20%)
Sarah Ketterer 516,115 sh (+8.12%)
Scott Black 178,437 sh (+1.60%)
Ken Fisher 13,246,593 sh (+1.44%)
Mario Gabelli 4,700 sh (unchged)
Francis Chou 410,000 sh (unchged)
David Dreman 1,102 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes 2,560,460 sh (-0.52%)
Murray Stahl 26,000 sh (-0.71%)
Barrow, Hanley, Mewhinney & Strauss 29,961,207 sh (-0.87%)
PRIMECAP Management 3,756,457 sh (-5.45%)
HOTCHKIS & WILEY 10,701,542 sh (-9.17%)
NWQ Managers 2,636,361 sh (-32.87%)
» More
Q3 2015

SNY Guru Trades in Q3 2015

Paul Tudor Jones 5,809 sh (New)
Sarah Ketterer 574,783 sh (+11.37%)
Murray Stahl 27,000 sh (+3.85%)
John Buckingham 133,116 sh (+0.70%)
Ken Fisher 13,295,966 sh (+0.37%)
Dodge & Cox 49,859,813 sh (+0.19%)
Bill Nygren 5,670,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Lee Ainslie 101,650 sh (unchged)
Mario Gabelli 4,700 sh (unchged)
Francis Chou 410,000 sh (unchged)
David Dreman 1,102 sh (unchged)
Manning & Napier Advisors, Inc 2,819,031 sh (-2.09%)
Barrow, Hanley, Mewhinney & Strauss 29,123,564 sh (-2.80%)
Scott Black 173,432 sh (-2.80%)
NWQ Managers 2,501,826 sh (-5.10%)
Charles Brandes 2,290,031 sh (-10.56%)
HOTCHKIS & WILEY 9,035,695 sh (-15.57%)
PRIMECAP Management 2,939,082 sh (-21.76%)
» More
Q4 2015

SNY Guru Trades in Q4 2015

HOTCHKIS & WILEY 10,141,383 sh (+12.24%)
Murray Stahl 28,300 sh (+4.81%)
Barrow, Hanley, Mewhinney & Strauss 29,489,368 sh (+1.26%)
Ken Fisher 13,416,220 sh (+0.90%)
Dodge & Cox 49,915,073 sh (+0.11%)
Mario Gabelli 4,700 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Paul Tudor Jones 5,809 sh (unchged)
David Dreman Sold Out
Scott Black Sold Out
Charles Brandes 2,198,827 sh (-3.98%)
PRIMECAP Management 2,767,582 sh (-5.84%)
John Buckingham 124,012 sh (-6.84%)
Lee Ainslie 91,300 sh (-10.18%)
NWQ Managers 2,078,119 sh (-16.94%)
Sarah Ketterer 428,923 sh (-25.38%)
Manning & Napier Advisors, Inc 281,917 sh (-90.00%)
» More
Q1 2016

SNY Guru Trades in Q1 2016

Joel Greenblatt 34,720 sh (New)
David Dreman 1,870 sh (New)
Charles Brandes 3,556,721 sh (+61.76%)
Paul Tudor Jones 8,259 sh (+42.18%)
Dodge & Cox 53,530,129 sh (+7.24%)
Ken Fisher 13,546,950 sh (+0.97%)
HOTCHKIS & WILEY 10,164,994 sh (+0.23%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli Sold Out
Lee Ainslie Sold Out
Barrow, Hanley, Mewhinney & Strauss 29,087,790 sh (-1.36%)
John Buckingham 122,234 sh (-1.43%)
Murray Stahl 27,697 sh (-2.13%)
Manning & Napier Advisors, Inc 275,505 sh (-2.27%)
NWQ Managers 1,946,427 sh (-6.34%)
PRIMECAP Management 2,549,382 sh (-7.88%)
Sarah Ketterer 391,613 sh (-8.70%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Sanofi SA is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products.

Sanofi SA was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.

Ratios

vs
industry
vs
history
P/E(ttm) 22.04
SNY's P/E(ttm) is ranked higher than
62% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. SNY: 22.04 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s P/E(ttm) Range Over the Past 10 Years
Min: 9.64  Med: 20.89 Max: 38.97
Current: 22.04
9.64
38.97
Forward P/E 12.59
SNY's Forward P/E is ranked higher than
58% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. SNY: 12.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.04
SNY's PE(NRI) is ranked higher than
63% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. SNY: 22.04 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s PE(NRI) Range Over the Past 10 Years
Min: 9.82  Med: 20.93 Max: 39.2
Current: 22.04
9.82
39.2
P/B 1.63
SNY's P/B is ranked higher than
72% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SNY: 1.63 )
Ranked among companies with meaningful P/B only.
SNY' s P/B Range Over the Past 10 Years
Min: 1.11  Med: 1.69 Max: 2.38
Current: 1.63
1.11
2.38
P/S 2.76
SNY's P/S is ranked higher than
51% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. SNY: 2.76 )
Ranked among companies with meaningful P/S only.
SNY' s P/S Range Over the Past 10 Years
Min: 1.72  Med: 2.81 Max: 3.94
Current: 2.76
1.72
3.94
EV-to-EBIT 17.71
SNY's EV-to-EBIT is ranked higher than
58% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. SNY: 17.71 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.3  Med: 19.30 Max: 200.9
Current: 17.71
8.3
200.9
EV-to-EBITDA 12.96
SNY's EV-to-EBITDA is ranked higher than
66% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. SNY: 12.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.4  Med: 12.80 Max: 129.7
Current: 12.96
5.4
129.7
Shiller P/E 20.33
SNY's Shiller P/E is ranked higher than
82% of the 146 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.77 vs. SNY: 20.33 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s Shiller P/E Range Over the Past 10 Years
Min: 12.53  Med: 21.29 Max: 28.21
Current: 20.33
12.53
28.21
Current Ratio 1.72
SNY's Current Ratio is ranked lower than
66% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. SNY: 1.72 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.72 Max: 2.71
Current: 1.72
0.79
2.71
Quick Ratio 1.36
SNY's Quick Ratio is ranked lower than
65% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. SNY: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.26 Max: 2.41
Current: 1.36
0.46
2.41
Days Inventory 139.55
SNY's Days Inventory is ranked lower than
63% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. SNY: 139.55 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 170.45  Med: 192.11 Max: 378.14
Current: 139.55
170.45
378.14
Days Sales Outstanding 79.53
SNY's Days Sales Outstanding is ranked lower than
55% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. SNY: 79.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.19  Med: 74.14 Max: 83.73
Current: 79.53
61.19
83.73
Days Payable 131.68
SNY's Days Payable is ranked higher than
79% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. SNY: 131.68 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 99.74  Med: 125.26 Max: 326.59
Current: 131.68
99.74
326.59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.98
SNY's Dividend Yield is ranked higher than
89% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. SNY: 3.98 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s Dividend Yield Range Over the Past 10 Years
Min: 1.7  Med: 3.70 Max: 5.46
Current: 3.98
1.7
5.46
Dividend Payout 0.87
SNY's Dividend Payout is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. SNY: 0.87 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s Dividend Payout Range Over the Past 10 Years
Min: 0.27  Med: 0.62 Max: 1
Current: 0.87
0.27
1
Dividend Growth (3y) 2.50
SNY's Dividend Growth (3y) is ranked lower than
62% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. SNY: 2.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 29.6
Current: 2.5
0
29.6
Forward Dividend Yield 4.05
SNY's Forward Dividend Yield is ranked higher than
87% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. SNY: 4.05 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.75
SNY's Yield on cost (5-Year) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. SNY: 4.75 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.03  Med: 4.42 Max: 6.52
Current: 4.75
2.03
6.52
3-Year Average Share Buyback Ratio 0.90
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. SNY: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: 0.00 Max: 2.2
Current: 0.9
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.74
SNY's Price/Tangible Book is ranked lower than
92% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. SNY: 14.74 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.22  Med: 14.15 Max: 41.94
Current: 14.74
7.22
41.94
Price/Projected FCF 4.01
SNY's Price/Projected FCF is ranked higher than
76% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. SNY: 4.01 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.92  Med: 1.23 Max: 1.56
Current: 4.01
0.92
1.56
Price/Median PS Value 0.98
SNY's Price/Median PS Value is ranked higher than
63% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. SNY: 0.98 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.08 Max: 2.69
Current: 0.98
0.64
2.69
Price/Graham Number 3.84
SNY's Price/Graham Number is ranked lower than
76% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. SNY: 3.84 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.99  Med: 4.34 Max: 6.54
Current: 3.84
1.99
6.54
Earnings Yield (Greenblatt) (%) 5.66
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. SNY: 5.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 5.20 Max: 12
Current: 5.66
0.5
12
Forward Rate of Return (Yacktman) (%) -3.94
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 323 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. SNY: -3.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.1  Med: 16.80 Max: 44.3
Current: -3.94
-6.1
44.3

More Statistics

Revenue (TTM) (Mil) $37,751
EPS (TTM) $ 1.85
Beta1.01
Short Percentage of Float0.20%
52-Week Range $37.63 - 54.98
Shares Outstanding (Mil)2,611.39

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 40,508 40,718 43,695
EPS ($) 3.01 3.05 3.37
EPS without NRI ($) 3.01 3.05 3.37
EPS Growth Rate
(3Y to 5Y Estimate)
2.44%
» More Articles for NYSE:SNY

Headlines

Articles On GuruFocus.com
Endonovo Therapeutics: Innovative Treatment, Catalyst Create Compelling Opportunity May 22 2016 
Charles Brandes Trims Stake in South American Petroleum Company May 13 2016 
Warren Buffett’s Top 5 Dividend Yielding Stocks Apr 26 2016 
Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Sanofi's New Products Will Fuel Sales Mar 13 2016 
Warren Buffett's Worst Performing Stocks Mar 03 2016 
Dodge & Cox Global Stock Fund 4th Quarter Commentary Jan 19 2016 
Dodge & Cox Stock Fund 2015 Commentary Jan 18 2016 
Why MannKind Could Be a Value Trap Jan 04 2016 

More From Other Websites
Sanofi Moves To Replace Medivation’s Board As New Buyers Rumored May 25 2016
Novo Nordisk IDegLira Recommended by FDA Advisory Committee May 25 2016
Alnylam Soars as Drugmakers Circle Rival Biotechnology Company May 25 2016
Medivation: Three Biotech Giants Enter. Which One Leaves? May 25 2016
[$$] Sanofi Moves to Replace Medivation Board May 25 2016
[$$] Sanofi seeks to oust entire Medivation board May 25 2016
Why Sanofi SA (ADR) (SNY) Is Trending on Wednesday May 25 2016
Stocks climb for the second day as energy companies jump May 25 2016
Sanofi Plays Game of Chicken With Medivation May 25 2016
Major Developments for Sanofi in 1Q16 May 25 2016
Sanofi wants to dump Medivation's board after rejected deal May 25 2016
Sanofi wants to dump Medivation's board after rejected deal May 25 2016
Medivation Advises Its Shareholders To Spurn Sanofi's Move To Replace Entire Board May 25 2016
Sanofi Moves to Oust Medivation Board May 25 2016
Sanofi moves to oust Medivation board in $9.3 billion takeover fight May 25 2016
Sanofi moves to oust Medivation board in $9.3 billion takeover fight May 25 2016
Sanofi moves to oust Medivation board in $9.3 bln takeover fight May 25 2016
France's Sanofi seeks to sack board of US takeover prey May 25 2016
Faber Report: Sanofi seeks to replace Medivation board May 25 2016
Celgene, Gilead Said to Join Suitors Mulling Medivation Bids May 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)